E-viri
Recenzirano
-
Forgie, Jennifer, RN; Santucci, Stephanie, RN; Pham, Diana; Gavigan, Genevieve, MASc, MD; Pratt, Melanie, MD; Fahim, Simone, MD; O'Quinn, John W., MD; Yang, William H., MD
Journal of allergy and clinical immunology, 02/2015, Letnik: 135, Številka: 2Journal Article
Methods After receiving a diagnosis of CSU with inadequate response to H1-antihistamines, and oral prednisone, patients completed a quality of life (QoL) questionnaire prior to beginning treatment with Omalizumab and every two weeks throughout the treatment.
